Taken together, DDX17 promoted tumor growth and facilitated HCC metastasis, whereas the CXCR1/2 inhibitor, Reparixin, reversed the oncogenic effect of DDX17 in HCC progression. This evidence concerns the gene DDX17 and hepatocellular carcinoma.